Changes in fibrinolysis in patients with localized tumors.

[1]  R L Bick,et al.  Alterations of Hemostasis Associated With Malignancy: Etiology, Pathophysiology, Diagnosis and Management , 2008, Seminars in thrombosis and hemostasis.

[2]  P. Mannucci,et al.  Early presence of activated ('exhausted') platelets in malignant tumors (breast adenocarcinoma and malignant melanoma). , 1989, European journal of cancer & clinical oncology.

[3]  G. Lowe,et al.  In Vivo Measurements of Fibrin Formation and Fibrinolysis in Operable Breast Cancer , 1989, Thrombosis and Haemostasis.

[4]  E. Kruithof,et al.  Plasminogen Activator Inhibitor 1 and Plasminogen Activator Inhibitor 2 in Various Disease States , 1988, Thrombosis and Haemostasis.

[5]  K. Huber,et al.  Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas , 1987 .

[6]  J. T. ten Cate,et al.  Increased Plasminogen Activator Inhibition Levels in Malignancy , 1987, Thrombosis and Haemostasis.

[7]  P. Mannucci,et al.  Hemostatic alterations are unrelated to the stage of tumor in untreated malignant melanoma and breast carcinoma. , 1985, European journal of cancer & clinical oncology.

[8]  J. Verheijen,et al.  Evidence for the Occurrence of a Fast-Acting Inhibitor for Tissue-Type Plasminogen Activator in Human Plasma , 1984, Thrombosis and Haemostasis.

[9]  R. Bertina,et al.  Stanozolol-Induced Changes in Fibrinolysis and Coagulation in Healthy Adults , 1984, Thrombosis and Haemostasis.

[10]  G. Markus.  The Role of Hemostasis and Fibrinolysis in the Metastatic Spread of Cancer , 1984, Seminars in thrombosis and hemostasis.

[11]  F. Rickles,et al.  Activation of blood coagulation in cancer: Trousseau's syndrome revisited. , 1983, Blood.

[12]  K. Tanaka,et al.  Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma. , 1982, British Journal of Cancer.

[13]  M. Blombäck,et al.  Measurement in human blood of fibrinogen/fibrin fragments containing the bβ 15–42 sequence , 1982 .

[14]  D. Collen,et al.  Histidine-rich glycoprotein in a normal and a clinical population. , 1981, Thrombosis research.

[15]  C. Kluft.  Studies on the Fibrinolytic System in Human Plasma: Quantitative Determination of Plasminogen Activators and Proactivators , 1979, Thrombosis and Haemostasis.

[16]  C. Kluft.  C1-inactivator-resistant fibrinolytic activity in plasma euglobulin fractions: its relation to vascular activator in blood and its role in euglobulin fibrinolysis. , 1978, Thrombosis Research.

[17]  A. Teger‐Nilsson,et al.  Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. , 1977, Scandinavian journal of clinical and laboratory investigation.

[18]  P. Dombernowsky,et al.  Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. , 1988, The Journal of laboratory and clinical medicine.

[19]  J. Verheijen,et al.  The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. , 1985, Scandinavian journal of clinical and laboratory investigation.

[20]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[21]  K. Tanaka,et al.  Effects of tranexamic acid and urokinase on hematogenous metastases of Lewis lung carcinoma in mice. , 1981, Invasion & metastasis.

[22]  C. Rudenstam,et al.  Fibrinolysis in human malignant tumours. , 1973, Acta chirurgica Scandinavica.